Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
We must try to make the health care system more accessible for people with disabilities
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated
